Dipeptidyl peptidase 4 inhibitor sitagliptin decreases myocardial fibrosis and modulates myocardial insulin signaling in a swine model of chronic myocardial ischemia
Open Access
- 29 July 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (7) , e0307922
Abstract
Objective: Although both clinical data and animal models suggest cardiovascular benefits following administration of Dipeptidyl Peptidase 4 (DPP-4) inhibitors, the underlying mechanisms remain unclear. We therefore sought to evaluate the effect of the DPP-4 inhibitor sitagliptin on myocardial fibrosis, and insulin signaling in chronic myocardial ischemia using a swine model. An ameroid constrictor placement on the left coronary circumflex artery of thirteen Yorkshire swine to model chronic myocardial ischemia. After two weeks of recovery, swine were assigned to one of two groups: control (CON, n = 8), or sitagliptin 100mg daily (SIT, n = 5). After 5 weeks of treatment, the swine underwent terminal harvest with collection of myocardial tissue. Fibrosis was quantified using Masson’s trichrome. Protein expression was quantified by Immunoblotting. Trichrome stain demonstrated a significant decrease in perivascular and interstitial fibrosis in the SIT group relative to CON (all p<0.05). Immunoblot showed a reduction in Jak2, the pSTAT3 to STAT 3 Ratio, pSMAD 2/3, and SMAD 2/3, and an increase in STAT 3 in the SIT group relative to CON (all p<0.05). SIT treatment was associated with increased expression of insulin receptor one and decreased expression of makers for insulin resistance, including phospho-PKC- alpha, RBP-4, SIRT1, and PI3K (p<0.05). Sitagliptin results in a reduction in perivascular and interstitial fibrosis and increased insulin sensitivity in chronically ischemic swine myocardium. This likely contributes to the improved cardiovascular outcomes seen with DPP-4 inhibitors.Keywords
Funding Information
- National Institutes of Health (Institute R01HL46716 and R01HL128831)
- National Institutes of Health (R01HL133624 and R56HL133624-05)
- National Institutes of Health (1F32HL160063-01)
This publication has 39 references indexed in Scilit:
- Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and DiabetesJACC: Asia, 2023
- Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 DiabetesJAMA, 2019
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialThe Lancet, 2019
- The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesisNature Communications, 2019
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal RiskJAMA, 2019
- New insights into TGF-β/Smad signaling in tissue fibrosisChemico-Biological Interactions, 2018
- QuPath: Open source software for digital pathology image analysisScientific Reports, 2017
- Therapeutic neovascularization for coronary disease: current state and future prospectsBasic Research in Cardiology, 2011
- SIRT1 and insulin resistanceNature Reviews Endocrinology, 2009
- Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic SubjectsNew England Journal of Medicine, 2006